secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2026-07-30T20:18:32+00:00
Accession:  0001384101-26-000042
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q2 revenue up 15% to $150.3M; launches Prosigna and TrueMRD
--------------------------------------------------------------------

- Total revenue $150.3M (+15% YoY); testing revenue $145.7M (+19%); Decipher +20%, Afirma +18%.
- GAAP net income $25.5M (17% of revenue); adjusted EBITDA $44.0M (29.2% of revenue).
- Launched Prosigna LDT for early-stage HR+ breast cancer and TrueMRD for MIBC; secured Medicare coverage for TrueMRD.
- Cash from ops $45.8M; cash & investments $485.2M as of June 30, 2026.
- Total testing volume up 14% to 48,389 tests; Decipher tests +17%, Afirma +10%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000042/0001384101-26-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410126000042/vcyt-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001384101-26-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer